CYP19A1 and breast carcinoma: Across all ages, a 2.5-year duration of aromatase inhibitors therapy resulted in more breast cancer deaths than 5-years, but the reduction in breast cancer deaths due to extending endocrine therapy duration from 5 to 10 years was small, especially for aromatase inhibitors regimens (Table 4).